TABLE 1.
Variable | Overall (n = 63) | rPLND (n = 22) | oPLND (n = 41) | p value |
---|---|---|---|---|
Age, median (IQR) | 65 (53–75) | 64 (52–74.8) | 65 (53–75) | 0.79 |
Sex [n (%)] | ||||
Male | 23 (36.5) | 9 (40.9) | 14 (34.1) | 0.8 |
Female | 40 (63.5) | 13 (59.1) | 27 (65.9) | |
BMI [median (IQR)] | 29.1 (25.9–32) | 26.8 (22.3–31.8) | 29.3 (26.7–32.1) | 0.26 |
Location of primary tumor [n (%)] | ||||
Unknown | 9 (14.3) | 3 (13.6) | 6 (14.6) | 0.99 |
Buttock/flank | 11 (17.5) | 4 (18.2) | 7 (17.1) | |
Lower extremity | 43 (68.2) | 15 (68.2) | 28 (68.2) | |
Breslow depth of primary tumor [mm; median (IQR)] | 3.5 (1.6–5.2) | 3.5 (2.4–5.5) | 3.5 (1.5–5.0) | 0.63 |
Systemic therapy before PLND [n (%)] | 18 (28.6) | 7 (31.8) | 11 (26.8) | 0.9 |
Systemic therapy after PLND [n (%)] | 40 (63.5) | 12 (54.5) | 28 (63.8) | 0.42 |
Indication for pelvic lymph node dissection [n (%)] | 0.04 | |||
Radiographic evidence/biopsy proven pelvic disease | 48 (76.2) | 14 (63.6) | 34 (82.9) | |
Pelvic drainage on SLNB (not sampled) in setting of positive inguinal SLN | 9 (14.3) | 6 (27.3) | 3 (7.3) | |
Involvement of 3 or more positive inguinal nodes | 4 (6.3) | 2 (9.1) | 2 (4.9) | |
Large (> 3 cm) positive groin disease | 2 (3.2) | 0 | 2 (4.9) |
rPLND robotic pelvic lymph node dissection; oPLND open pelvic lymph node dissection; IQR interquartile range; BMI body mass index; PLND pelvic lymph node dissection; SLNB sentinel lymph node biopsy; SLN sentinel lymph node